Eventide Gilead Fund
ETGLX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 4221 North 203rd Street, Suite 100 Elkhorn NE United States of America 68022-3474
- IPO Date
- Jul 2, 2008
- CIK
- 0001355064
- Website
- eventideinvestments.com
- Similar Companies
- Business
- Eventide Gilead Fund (ETGLX) is a diversified mutual fund managed by Eventide Asset Management, LLC that seeks long-term capital appreciation by investing primarily in a broad range of equity securities across market capitalizations, with historical emphases on small- and mid-cap growth stocks in the health care and information technology sectors; it employs a thematic approach targeting companies positioned for long-term secular trends while prioritizing those that create value for society, employees, suppliers, communities, and the environment through ethical and sustainable practices. The fund offers multiple share classes including Class N (ETGLX, inception July 8, 2008), Class I (ETILX, inception February 2, 2010), Class A (ETAGX), and Class C (ETCGX), with total assets under management of approximately $2.97 billion as of late 2025; it maintains a portfolio of around 68 holdings featuring top positions such as Xometry Inc. (AI-enabled on-demand manufacturing), Guardant Health Inc. (cancer cell diagnostics), Mirum Pharmaceuticals Inc. (rare pediatric disease treatments), Toast Inc. (restaurant cloud software), Trane Technologies plc (energy-efficient HVAC systems), iRhythm Technologies Inc. (wearable cardiac monitoring), United Rentals Inc. (equipment rental services), GE Vernova Inc. (renewable energy and grid solutions), Verona Pharma plc (respiratory disease therapies), and Lam Research Corp. (semiconductor manufacturing equipment). Eventide Asset Management, founded in 2008 and headquartered in Boston, Massachusetts, positions the fund as a non-correlated return source with high internal diversification and low market correlation relative to the Bloomberg U.S. Mid-Cap Growth Index benchmark. In recent developments, the fund has seen portfolio adjustments including a 32.8% increase in holdings of TG Therapeutics Inc. during the second quarter of 2025 and a 4.8% boost in Royalty Pharma plc shares, reflecting ongoing active management amid sector emphases in healthcare innovation and technology; as of September 30, 2025, it reported strong year-to-date performance of 21.72% for Class N shares, outperforming the benchmark, with a Morningstar 3-star rating in the U.S. mid-cap growth category.